|
ASNSD1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.54980472899524E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.16129994509606E-09 |
| Normal-vs-Stage2 |
7.12500000110694E-08 |
| Normal-vs-Stage3 |
9.56239998295416E-09 |
| Normal-vs-Stage4 |
3.37979999542881E-09 |
| Stage1-vs-Stage2 |
6.155900E-02 |
| Stage1-vs-Stage3 |
3.066400E-01 |
| Stage1-vs-Stage4 |
1.420380E-01 |
| Stage2-vs-Stage3 |
3.460200E-01 |
| Stage2-vs-Stage4 |
6.854400E-01 |
| Stage3-vs-Stage4 |
5.278000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.40739975229565E-10 |
| Normal-vs-AfricanAmerican |
7.47039999970944E-07 |
| Normal-vs-Asian |
6.08189999999897E-05 |
| Caucasian-vs-AfricanAmerican |
2.269600E-01 |
| Caucasian-vs-Asian |
2.426000E-01 |
| AfricanAmerican-vs-Asian |
4.772400E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.17640008845399E-10 |
| Normal-vs-Female |
2.25329976899502E-10 |
| Male-vs-Female |
3.053600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.97559996034857E-09 |
| Normal-vs-Age(41-60Yrs) |
1.76000003460075E-09 |
| Normal-vs-Age(61-80Yrs) |
1.91399995852493E-09 |
| Normal-vs-Age(81-100Yrs) |
1.806400E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.619600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.635600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.074000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.485800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.541000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.134800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.076800E-01 |
| Classical-VS-Follicular |
8.234700E-04 |
| Classical-VS-Other |
2.368000E-01 |
| Classical-VS-Normal |
3.11740000480398E-09 |
| Tall-VS-Follicular |
2.848200E-01 |
| Tall-VS-Other |
6.492000E-01 |
| Tall-VS-Normal |
1.57691999999043E-05 |
| Follicular-VS-Other |
8.748800E-01 |
| Follicular-VS-Normal |
4.80690043325183E-10 |
| Other-VS-Normal |
4.276500E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.05969996613931E-09 |
| Normal-vs-N1 |
1.37319999815588E-09 |
| N0-vs-N1 |
2.710400E-01 |
|
|
